326 related articles for article (PubMed ID: 32065106)
21. Beyond the Selective Inhibition of Histone Deacetylase 6.
Rodrigues DA; Thota S; Fraga CA
Mini Rev Med Chem; 2016; 16(14):1175-84. PubMed ID: 27121714
[TBL] [Abstract][Full Text] [Related]
22. Methods for the expression, purification, and crystallization of histone deacetylase 6-inhibitor complexes.
Osko JD; Christianson DW
Methods Enzymol; 2019; 626():447-474. PubMed ID: 31606087
[TBL] [Abstract][Full Text] [Related]
23. Selective pharmacological inhibitors of HDAC6 reveal biochemical activity but functional tolerance in cancer models.
Depetter Y; Geurs S; De Vreese R; Goethals S; Vandoorn E; Laevens A; Steenbrugge J; Meyer E; de Tullio P; Bracke M; D'hooghe M; De Wever O
Int J Cancer; 2019 Aug; 145(3):735-747. PubMed ID: 30694564
[TBL] [Abstract][Full Text] [Related]
24. Design, Synthesis, Bioactivity Evaluation, Crystal Structures, and In Silico Studies of New α-Amino Amide Derivatives as Potential Histone Deacetylase 6 Inhibitors.
Xu Y; Tang H; Xu Y; Guo J; Zhao X; Meng Q; Xiao J
Molecules; 2022 May; 27(10):. PubMed ID: 35630812
[TBL] [Abstract][Full Text] [Related]
25. Structure-based design generated novel hydroxamic acid based preferential HDAC6 lead inhibitor with on-target cytotoxic activity against primary choroid plexus carcinoma.
Kassab SE; Mowafy S; Alserw AM; Seliem JA; El-Naggar SM; Omar NN; Awad MM
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1062-1077. PubMed ID: 31072216
[TBL] [Abstract][Full Text] [Related]
26. Recent development of selective inhibitors targeting the HDAC6 as anti-cancer drugs: Structure, function and design.
Peng J; Xie F; Qin P; Liu Y; Niu H; Sun J; Xue H; Zhao Q; Liu J; Wu J
Bioorg Chem; 2023 Sep; 138():106622. PubMed ID: 37244230
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors.
Senger J; Melesina J; Marek M; Romier C; Oehme I; Witt O; Sippl W; Jung M
J Med Chem; 2016 Feb; 59(4):1545-55. PubMed ID: 26653328
[TBL] [Abstract][Full Text] [Related]
28. HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics.
Laino AS; Betts BC; Veerapathran A; Dolgalev I; Sarnaik A; Quayle SN; Jones SS; Weber JS; Woods DM
J Immunother Cancer; 2019 Feb; 7(1):33. PubMed ID: 30728070
[TBL] [Abstract][Full Text] [Related]
29. Design and synthesis of novel histone deacetylase 6 inhibitors with benzyl-triazole as the core skeleton.
Mou Z; Gao J; Miao H; Zhang L; Su L; Wang B; Luan Y
Biosci Trends; 2019 Jul; 13(3):267-272. PubMed ID: 31155552
[TBL] [Abstract][Full Text] [Related]
30. Pharmacological modulation of HDAC1 and HDAC6 in vivo in a zebrafish model: Therapeutic implications for Parkinson's disease.
Pinho BR; Reis SD; Guedes-Dias P; Leitão-Rocha A; Quintas C; Valentão P; Andrade PB; Santos MM; Oliveira JM
Pharmacol Res; 2016 Jan; 103():328-39. PubMed ID: 26657418
[TBL] [Abstract][Full Text] [Related]
31. PTG-0861: A novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemia.
Gawel JM; Shouksmith AE; Raouf YS; Nawar N; Toutah K; Bukhari S; Manaswiyoungkul P; Olaoye OO; Israelian J; Radu TB; Cabral AD; Sina D; Sedighi A; de Araujo ED; Gunning PT
Eur J Med Chem; 2020 Sep; 201():112411. PubMed ID: 32615502
[TBL] [Abstract][Full Text] [Related]
32. Discovery of a fluorescent probe with HDAC6 selective inhibition.
Zhang Y; Yan J; Yao TP
Eur J Med Chem; 2017 Dec; 141():596-602. PubMed ID: 29102179
[TBL] [Abstract][Full Text] [Related]
33. Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present).
Zhao C; Dong H; Xu Q; Zhang Y
Expert Opin Ther Pat; 2020 Apr; 30(4):263-274. PubMed ID: 32008402
[No Abstract] [Full Text] [Related]
34. A novel class of anthraquinone-based HDAC6 inhibitors.
Song Y; Lim J; Seo YH
Eur J Med Chem; 2019 Feb; 164():263-272. PubMed ID: 30597327
[TBL] [Abstract][Full Text] [Related]
35. Difluoromethyl-1,3,4-oxadiazoles are slow-binding substrate analog inhibitors of histone deacetylase 6 with unprecedented isotype selectivity.
Cellupica E; Caprini G; Cordella P; Cukier C; Fossati G; Marchini M; Rocchio I; Sandrone G; Vanoni MA; Vergani B; Źrubek K; Stevenazzi A; Steinkühler C
J Biol Chem; 2023 Jan; 299(1):102800. PubMed ID: 36528061
[TBL] [Abstract][Full Text] [Related]
36. The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
Negmeldin AT; Pflum MKH
Bioorg Med Chem Lett; 2017 Aug; 27(15):3254-3258. PubMed ID: 28648461
[TBL] [Abstract][Full Text] [Related]
37. An assessment of crucial structural contributors of HDAC6 inhibitors through fragment-based non-linear pattern recognition and molecular dynamics simulation approaches.
Banerjee S; Jana S; Jha T; Ghosh B; Adhikari N
Comput Biol Chem; 2024 Jun; 110():108051. PubMed ID: 38520883
[TBL] [Abstract][Full Text] [Related]
38. Development of the first non-hydroxamate selective HDAC6 degraders.
Keuler T; König B; Bückreiß N; Kraft FB; König P; Schäker-Hübner L; Steinebach C; Bendas G; Gütschow M; Hansen FK
Chem Commun (Camb); 2022 Oct; 58(79):11087-11090. PubMed ID: 36098075
[TBL] [Abstract][Full Text] [Related]
39. Carboxylic acid derivatives display potential selectivity for human histone deacetylase 6: Structure-based virtual screening, molecular docking and dynamics simulation studies.
Uba AI; Yelekçi K
Comput Biol Chem; 2018 Aug; 75():131-142. PubMed ID: 29859380
[TBL] [Abstract][Full Text] [Related]
40. Recent Development of Novel HDAC6 Isoform-selective Inhibitors.
Zhao Y; Liang T; Hou X; Fang H
Curr Med Chem; 2021; 28(21):4133-4151. PubMed ID: 33176627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
